Pfizer Inc. (NYSE:PFE) Shares Sold by Emfo LLC

Emfo LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 54.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 3,221 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Emfo LLC’s holdings in Pfizer were worth $93,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Worth Asset Management LLC purchased a new stake in Pfizer during the 1st quarter worth $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer during the 3rd quarter valued at about $30,000. Sanctuary Wealth Management L.L.C. acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $50,000. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC lifted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PFE shares. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $36.88.

Pfizer Stock Up 0.2 %

Pfizer stock traded up $0.04 during trading hours on Monday, hitting $25.90. The company had a trading volume of 35,623,531 shares, compared to its average volume of 42,737,133. The firm has a market capitalization of $146.66 billion, a P/E ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm’s fifty day moving average is $27.28 and its 200-day moving average is $28.88. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $41.33.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.14 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.